Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 21, Number 3—March 2015
Dispatch

Moxifloxacin Prophylaxis against MDR TB, New York, New York, USA

Lisa TrieuComments to Author , Douglas C. Proops, and Shama D. Ahuja
Author affiliations: New York City Department of Health and Mental Hygiene, Bureau of Tuberculosis Control, New York, New York, USA

Main Article

Table 1

Current recommendations of international public health agencies for managing multidrug-resistant tuberculosis infection among contacts of infected persons

Recommendation
Treatment with isoniazid alone if high likelihood that the contact had prior exposure to and infection caused by a drug-susceptible case (2,4)
Treatment with >2 antimicrobial drugs to which the index case is susceptible, including pyrazinamide and ethambutol (1,2,4,5)
Treatment with pyrazinamide or ethambutol and a fluoroquinolone (1,2,4)
Clinical monitoring for 2 years for signs or symptoms of active disease (2,3)

Main Article

References
  1. American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med. 2000;161:S221–47 and. DOIPubMedGoogle Scholar
  2. Curry International Tuberculosis Center and California Department of Public Health. Drug-resistant tuberculosis: a survival guide for clinicians. 2nd ed. San Francisco; 2011 [cited 2014 Dec 19]. http://www.currytbcenter.ucsf.edu/drtb/
  3. European Centre for Disease Prevention and Control. Management of contacts of MDR TB and XDR TB patients. Stockholm: The Centre; 2012 [cited 2014 Dec 19]. http://www.ecdc.europa.eu/en/publications/Publications/201203-Guidance-MDR-TB-contacts.pdf
  4. Centers for Disease Control and Prevention. Management of persons exposed to multidrug-resistant tuberculosis. MMWR Recomm Rep. 1992;41(RR-11):61–71 .PubMedGoogle Scholar
  5. New York City Department of Health and Mental Hygiene Bureau of Tuberculosis Control. Tuberculosis: clinical policies and protocols. 4th ed. New York: The Department; 2008 [cited 2014 Dec 19]. http://www.nyc.gov/html/doh/downloads/pdf/tb/tb-protocol.pdf
  6. World Health Organization. Guidelines on the management of latent tuberculosis infection. Geneva: The Organization; 2015 [cited 2014 Dec 19]. http://apps.who.int/iris/bitstream/10665/136471/1/9789241548908_eng.pdf?ua=1
  7. Sharma  SK, Mohan  A, Kadhiravan  T. HIV–TB co-infection: epidemiology, diagnosis & management. Indian J Med Res. 2005;121:550–67 .PubMedGoogle Scholar
  8. Markowitz  N, Hansen  NI, Hopewell  PC, Glassroth  J, Kvale  PA, Mangura  BT, Incidence of tuberculosis in the United States among HIV-infected persons. The Pulmonary Complications of HIV Infection Study Group. Ann Intern Med. 1997;126:123–32 and. DOIPubMedGoogle Scholar
  9. Schluger  NW, Burzynski  J. Tuberculosis and HIV infection: epidemiology, immunology, and treatment. HIV Clin Trials. 2001;2:356–65 and. DOIPubMedGoogle Scholar
  10. World Health Organization. Global tuberculosis report 2013. Geneva: The Organization; 2014 [cited 2014 Dec 19]. http://apps.who.int/iris/bitstream/10665/91355/1/9789241564656_eng.pdf
  11. Younossian  AB, Rochat  T, Ketterer  JP, Wacker  J, Janssens  JP. High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis. Eur Respir J. 2005;26:462–4 and. DOIPubMedGoogle Scholar
  12. Ridzon  R, Meador  J, Maxwell  R, Higgins  K, Weismuller  P, Onorato  IM. Asymptomatic hepatitis in persons who received alternative preventive therapy with pyrazinamide and ofloxacin. Clin Infect Dis. 1997;24:1264–5 and. DOIPubMedGoogle Scholar
  13. Horn  DL, Hewlett  D Jr, Alfalla  C, Peterson  S, Opal  SM. Limited tolerance of ofloxacin and pyrazinamide prophylaxis against tuberculosis. N Engl J Med. 1994;330:1241 and. DOIPubMedGoogle Scholar
  14. Papastavros  T, Dolovich  LR, Holbrook  A, Whitehead  L, Loeb  M. Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis. CMAJ. 2002;167:131–6 .PubMedGoogle Scholar
  15. Adler-Shohet  FC, Low  J, Carson  M, Girma  H, Singh  J. Management of latent tuberculosis infection in child contacts of multidrug-resistant tuberculosis. Pediatr Infect Dis J. 2014;33:664–6 and. DOIPubMedGoogle Scholar
  16. Bamrah  S, Dorina  F, Setik  L, Song  R, Kawamura  LM. A. Heetderks A, et al. Treatment for LTBI in contacts of MDR-TB patients, Federated States of Micronesia, 2009–2012. Int J Tuberc Lung Dis. 2014;18:912–8.

Main Article

Page created: February 20, 2015
Page updated: February 20, 2015
Page reviewed: February 20, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external